Sihe Zhang | Medicine | Distinguished Scientist Award

Distinguished Scientist Award

Sihe Zhang
Nankai University, China

Sihe Zhang
Affiliation Nankai University
Country China
Scopus ID 7409373738
Documents 55
Citations 1,269
h-index 16
Subject Area Medicine
Event Scientific World Research Awards
ORCID 0000-0002-8923-1993

The Distinguished Scientist Award recognizes the scholarly achievements of Sihe Zhang, Professor and Director at Nankai University School of Medicine. His research focuses on cancer biology, drug delivery systems, endocytosis, extracellular vesicles, antibody therapeutics, and translational medicine. Through sustained contributions to hepatocellular carcinoma and ovarian cancer research, he has developed innovative approaches that connect molecular mechanisms with therapeutic applications.[1]

Abstract

Sihe Zhang is a biomedical researcher whose work spans cancer biology, antibody engineering, cellular uptake mechanisms, extracellular vesicle biology, and targeted therapeutic delivery. His investigations have contributed to understanding macropinocytosis, endocytic recycling, tumor progression, and resistance mechanisms in hepatocellular and ovarian cancers. He has also participated in the development of innovative antibody-based therapies and nanomedicine strategies aimed at improving treatment specificity and efficacy. His publication portfolio demonstrates a sustained commitment to translational medical research and interdisciplinary collaboration, supporting advancements in cancer diagnosis, drug delivery, and precision medicine.[1][2]

Keywords

Cancer Biology; Drug Delivery; Endocytosis; Extracellular Vesicles; Antibody Therapeutics; Hepatocellular Carcinoma; Ovarian Cancer; Nanomedicine.

Introduction

Professor Zhang has held academic positions at Nankai University and previously at the Fourth Military Medical University. His career reflects long-term engagement with molecular medicine and cell biology, emphasizing mechanisms that influence cancer progression and treatment response.[1]

Research Profile

His research profile combines laboratory discovery with translational applications. Major themes include cellular trafficking, therapeutic antibodies, tumor microenvironment studies, and targeted delivery platforms designed to improve treatment outcomes in oncology.[1]

Research Contributions

Notable contributions include investigations into CD147-mediated signaling, extracellular vesicle uptake, macropinocytosis-driven drug resistance, and antibody-based cancer therapies. These studies have expanded understanding of tumor biology and therapeutic targeting strategies.[2][3]

Publications

His scholarly record includes 55 indexed publications. Representative works address hepatocellular carcinoma resistance mechanisms, extracellular vesicle biology, peptide delivery systems, anti-CD147 therapeutics, and nanobiotechnology-based treatment approaches.[2][4]

Research Impact

With 1,269 citations and an h-index of 16, his research has influenced studies in cancer therapeutics, molecular oncology, and biomedical engineering. The impact of his work is reflected through citations, collaborations, and peer-review activities across leading journals.[1]

Award Suitability

The breadth of Professor Zhang’s contributions, combined with sustained publication output and translational relevance, aligns with the objectives of the Scientific World Research Awards. His work demonstrates scientific rigor and practical relevance in medicine.[1]

Conclusion

Sihe Zhang has established a recognized research portfolio in cancer biology and therapeutic innovation. His scholarly achievements and ongoing contributions support recognition through the Distinguished Scientist Award.[1]

References

  1. ORCID. (2026). Sihe Zhang (0000-0002-8923-1993) Research Profile.https://orcid.org/0000-0002-8923-1993
  2. Qian, L., et al. (2025). The uptake of extracellular vesicles: Research progress in cancer drug resistance and beyond. Drug Resistance Updates.https://doi.org/10.1016/j.drup.2025.101209
  3. Qi, F.Z., et al. (2024). Hypoxia-activated ADCC-enhanced humanized anti-CD147 antibody. MedComm.https://doi.org/10.1002/mco2.512
  4. Sun, Z., et al. (2023). Cell-Penetrating Peptide-Based Delivery of Macromolecular Drugs. Biomedicines.https://doi.org/10.3390/biomedicines11071971
  5. Wang, B., et al. (2024). Hypoxia-activated selectivity-improved anti-PKM2 antibody combined with prodrug TH-302. International Journal of Biological Sciences.https://doi.org/10.7150/ijbs.92211

Yoshiya Tanaka | Medicine | Innovative Research Award

Innovative Research Award

Yoshiya Tanaka

Yoshiya Tanaka
Affiliation Hospital of University of Occupational and Environmental Health
Country Japan
Scopus ID 56328279400
Documents 1,326
Citations 50,831
h-index 99
Subject Area Medicine
Event Scientific World Research Awards

Yoshiya Tanaka, Hospital of University of Occupational and Environmental Health, Japan, is recognized for substantial contributions to rheumatology, immunology, and autoimmune disease research. His scholarly output, clinical investigations, and leadership in international collaborations have supported advancements in evidence-based medical practice and therapeutic development.[1]

Abstract

The Innovative Research Award recognizes researchers whose work demonstrates sustained scientific excellence and measurable impact. Yoshiya Tanaka has contributed extensively to rheumatology and clinical immunology through studies on autoimmune diseases, inflammatory mechanisms, biologic therapies, and targeted treatments. His research has informed clinical guidelines, improved disease classification systems, and supported the development of therapeutic strategies for conditions such as systemic lupus erythematosus, rheumatoid arthritis, and IgG4-related disease. With a substantial publication record and broad international collaboration, his work has influenced both academic research and patient care, reflecting the objectives of the Scientific World Research Awards.[1][2]

Keywords

Rheumatology, Clinical Immunology, Autoimmune Diseases, Rheumatoid Arthritis, Systemic Lupus Erythematosus, Biologic Therapy, Translational Medicine.

Introduction

Modern rheumatology depends on interdisciplinary research linking immunology, molecular biology, and clinical practice. Yoshiya Tanaka has participated in investigations that enhanced understanding of inflammatory pathways and treatment approaches for immune-mediated diseases.[3]

Research Profile

As Professor and Chairman in rheumatology and clinical immunology, Tanaka has developed a research portfolio focused on disease mechanisms, therapeutic innovation, and clinical trial leadership. His scholarly record reflects long-term engagement with translational medicine and global collaboration.[1]

Research Contributions

Key contributions include studies supporting lupus classification criteria, IgG4-related disease frameworks, Janus kinase inhibitor development, and biologic treatment evaluation. These efforts have contributed to improved disease assessment and therapeutic decision-making.[2][4]

Publications

  • 2019 EULAR/ACR Classification Criteria for Systemic Lupus Erythematosus.
  • Trial of Anifrolumab in Active Systemic Lupus Erythematosus.
  • Janus Kinase-Targeting Therapies in Rheumatology.

Research Impact

The researcher’s publications have received extensive citations, demonstrating influence across clinical medicine and immunology. Findings from collaborative studies have informed guidelines, therapeutic development, and evidence-based healthcare practices internationally.[1][5]

Award Suitability

The breadth of scientific output, citation performance, clinical relevance, and leadership in collaborative research aligns with the objectives of the Innovative Research Award. His contributions demonstrate sustained scholarly influence and practical significance in medicine.

Conclusion

Yoshiya Tanaka’s career reflects a consistent commitment to advancing knowledge in rheumatology and autoimmune disease research. His achievements support recognition within international scientific award programs and academic communities.

References

  1. Elsevier. (n.d.). Scopus author details: Yoshiya Tanaka, Author ID 56328279400. Scopus.
    https://www.scopus.com/authid/detail.uri?authorId=56328279400
  2. Aringer, M., et al. (2019). 2019 EULAR/ACR Classification Criteria for Systemic Lupus Erythematosus.
    DOI: https://doi.org/10.1002/art.40930
  3. Tanaka, Y., Adams, D.H., & Shaw, S. (1993). T-cell Adhesion Induced by Proteoglycan-Immobilized Cytokine MIP-1β.
    DOI: https://doi.org/10.1038/361079a0
  4. Tanaka, Y., Luo, Y., O’Shea, J.J., & Nakayamada, S. (2022). Janus Kinase-Targeting Therapies in Rheumatology.
    DOI: https://doi.org/10.1038/s41584-021-00726-8
  5. Google Scholar. (2026). Yoshiya Tanaka Citation Profile.
    https://scholar.google.com/citations?user=t_hAg7QAAAAJ&hl=en

Lina Posada Calderon | Medicine | Research Excellence Award

Dr. Lina Posada Calderon | Medicine | Research Excellence Award

Resident | New York Presbyterian | United States

Dr. Lina Posada Calderon is an accomplished biomedical researcher at Weill Cornell Medicine, New York, specializing in translational and molecular cancer research. Her work focuses on the clinical and molecular characterization of cancers, precision oncology, biomarker discovery, and genetic drivers of tumor progression, with particular emphasis on KRAS-mutated malignancies. She has strong expertise in molecular biology, cancer genomics, clinical data analysis, interdisciplinary research, and high-impact scientific publishing. Her research bridges laboratory discoveries with patient-centered clinical outcomes. Dr. Posada Calderon has published 12 Scopus-indexed documents, receiving 61 citations, and holds an h-index of 5, reflecting her growing scholarly impact and emerging leadership in precision cancer research.

 

Citation Metrics (Scopus)

61
45
30
15
0

Citations

61

Documents

12

h-index

5

Citations

Documents

h-index

View Scopus Profile
View Google Scholar

Featured Publications

 

Shinichiro Sawa | Medicine | Best Researcher Award

Dr. Shinichiro Sawa | Medicine | Best Researcher Award

Professor | Kyushu University | Japan 

Dr. Shinichiro Sawa is a highly accomplished Japanese immunologist and medical researcher renowned for his pioneering work in immune regulation, autoimmunity, and inflammation. He currently serves as a Professor at the Institute of Bioregulation, Kyushu University, Japan, where he leads innovative studies in molecular and cellular immunology. Dr. Sawa began his academic journey at Osaka University, earning his Medical Degree (M.D.) in 2000 and subsequently his Ph.D. in Medicine in 2006 from the same institution, where he developed a strong foundation in biomedical sciences and experimental medicine. His professional trajectory includes significant academic roles as Assistant Professor at the University of Tokyo (2011–2016) and Associate Professor at Hokkaido University’s Institute for Genetic Medicine (2016–2018) before joining Kyushu University in 2019. Dr. Sawa’s research interests center on understanding how immune cells, such as γδ T cells, fibroblasts, and plasma cells, interact with tissue environments to regulate immune tolerance, autoimmunity, and inflammatory diseases. His studies, published in prestigious journals such as Nature Immunology, Journal of Clinical Investigation, and Journal of Investigative Dermatology, have shed light on how fibroblasts contribute to central immune tolerance and how plasma cells promote osteoclastogenesis in autoimmune arthritis. His research skills encompass cellular immunology, molecular signaling analysis, animal modeling of immune diseases, flow cytometry, and translational immunopathology, demonstrating both depth and precision in experimental design and interpretation. Recognized for his scientific contributions, Dr. Sawa has received numerous academic honors and research recognitions throughout his career, reflecting his influence in the global immunology community. In conclusion, Dr. Shinichiro Sawa stands as a leading figure in immunological research, bridging basic science and clinical application to advance our understanding of immune homeostasis and to pave the way for novel therapeutic strategies against autoimmune and inflammatory disorders.

Profiles: Scopus | ORCID

Featured Publications

  1. Nonaka, D., Yoshida, S., Nakano, K., Li, X., Okamura, T., Umemoto, E., Yamada, T., Watanabe, M., Jinno, S., Ito, M., Tsuda, M., Noguchi, N., Jiang, X.-J., Sumiya, E., & Sawa, S. (2025). Fibroblast-derived CSF1 maintains colonization of gut mucosal macrophage to resist bacterial infection. Mucosal Immunology.

  2. Onji, M., Sigl, V., Lendl, T., Novatchkova, M., Ullate-Agote, A., Andersson-Rolf, A., Kozieradzki, I., Koglgruber, R., Pai, T.-P., Lichtscheidl, D., Nayak, K., Zilbauer, M., Carranza García, N.-A., Sievers, L., Falk-Paulsen, M., Cronin, S. J. F., Hagelkruys, A., Sawa, S., Osborne, L. C., Rosenstiel, P., Pasparakis, M., Ruland, J., Takayanagi, H., Clevers, H., Koo, B.-H., & Penninger, J. M. (2025). RANK drives structured intestinal epithelial expansion during pregnancy. Nature, 637(8044), 156–166.

  3. Nitta, T., Tsutsumi, M., Nitta, S., Muro, R., Suzuki, E. C., Nakano, K., Tomofuji, Y., Sawa, S., Okamura, T., Penninger, J. M., & Takayanagi, H. (2020). Fibroblasts as a source of self-antigens for central immune tolerance. Nature Immunology, 21(10), 1172–1180.

  4. Nagashima, K., Sawa, S., Nitta, T., Tsutsumi, M., Okamura, T., Penninger, J. M., Nakashima, T., & Takayanagi, H. (2017). Identification of subepithelial mesenchymal cells that induce IgA and diversify gut microbiota. Nature Immunology, 18(6), 675–682.

  5. Onder, L., Mörbe, U., Pikor, N., Novkovic, M., Cheng, H.-W., Hehlgans, T., Pfeffer, K., Becher, B., Waisman, A., Rülicke, T., Gommerman, J., Müller, C., Sawa, S., Scandella, E., & Ludewig, B. (2017). Lymphatic endothelial cells control initiation of lymph node organogenesis. Immunity, 47(1), 80–92.